Eagle Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Eagle Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-352,860	Closed	-$39.9M	–	615
2021 Q1	$39.9M	Buy	352,860 +25,307	+8%	+$3.45M	0.18%	181
2020 Q4	$45.3M	Sell	327,553 -23,268	-7%	-$2.76M	0.26%	146
2020 Q3	$29.9M	Buy	350,821 +75,574	+27%	+$6.26M	0.15%	191
2020 Q2	$20.3M	Buy	+275,247	New	+$18.2M	0.12%	213
2017 Q4	–	Sell	-475,875	Closed	-$27.3M	–	648
2017 Q3	$27.3M	Sell	475,875 -4,904	-1%	-$291K	0.16%	221
2017 Q2	$29.9M	Buy	480,779 +46,539	+11%	+$2.8M	0.18%	194
2017 Q1	$29.4M	Sell	434,240 -1,476	-0.3%	-$112K	0.19%	171
2016 Q4	$30.6M	Buy	435,716 +3,847	+0.9%	+$273K	0.2%	153
2016 Q3	$30.6M	Buy	431,869 +89,329	+26%	+$5.7M	0.21%	153
2016 Q2	$16.8M	Sell	342,540 -12,222	-3%	-$791K	0.12%	243
2016 Q1	$22.5M	Sell	354,762 -7,754	-2%	-$507K	0.16%	192
2015 Q4	$40.7M	Buy	362,516 +8,009	+2%	+$801K	0.27%	128
2015 Q3	$34.1M	Buy	+354,507	New	+$40.6M	0.23%	147

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Eagle Asset Management's RARE Position: Q2 2021 in Review

Eagle Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 352,860 shares — an estimated $39.9M sold.

Eagle Asset Management first reported a position in RARE in Q3 2015 and held it in 13 quarters. The position peaked at $45.3M in Q4 2020. 241 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

Eagle Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
Eagle Asset Management sold 352,860 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $39.9M.
Eagle Asset Management first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 13 quarters.
Eagle Asset Management's Ultragenyx Pharmaceutical position peaked at $45.3M in Q4 2020.
241 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Eagle Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.